A Schwitters1, M Kaggwa2, P Omiel3, G Nagadya3, N Kisa2, S Dalal3. 1. <label>*</label>Epidemic Intelligence Service, Division of Global HIV/AIDS, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA. 2. <label><sup>†</sup></label>Uganda Prisons Service, Kampala. 3. <label><sup>‡</sup></label>Division of Global HIV/AIDS, Center for Global Health, CDC, Entebbe, Uganda.
Abstract
BACKGROUND: The Uganda Prisons Service (UPS) is responsible for the health of approximately 32 500 inmates in 233 prisons. In 2008 a rapid UPS assessment estimated TB prevalence at 654/100 000, three times that of the general population (183/100 000). Although treatment programs exist, little is known about treatment completion in sub-Saharan African prisons. METHODS: We conducted a retrospective study of Ugandan prisoners diagnosed with TB from June 2011 to November 2012. We analyzed TB diagnosis, TB-HIV comorbidity and treatment completion from national registers and tracked prison transfers and releases. RESULTS: A total of 469 prisoners were diagnosed with TB over the 1.5-year period (incidence 955/100 000 person-years). Of 466 prisoners starting treatment, 48% completed treatment, 43% defaulted, 5% died and 4% were currently on treatment. During treatment, 12% of prisoners remaining in the same prison defaulted, 53% of transfers defaulted and 81% of those released were lost to follow-up. The odds of defaulting were 8.36 times greater among prisoners who were transferred during treatment. CONCLUSIONS: TB incidence and treatment default are high among Ugandan prisoners. Strategies to improve treatment completion and prevent multidrug resistance could include avoiding transfer of TB patients, improving communications between prisons to ensure treatment follow-up after transfer and facilitating transfer to community clinics for released prisoners.
BACKGROUND: The Uganda Prisons Service (UPS) is responsible for the health of approximately 32 500 inmates in 233 prisons. In 2008 a rapid UPS assessment estimated TB prevalence at 654/100 000, three times that of the general population (183/100 000). Although treatment programs exist, little is known about treatment completion in sub-Saharan African prisons. METHODS: We conducted a retrospective study of Ugandan prisoners diagnosed with TB from June 2011 to November 2012. We analyzed TB diagnosis, TB-HIV comorbidity and treatment completion from national registers and tracked prison transfers and releases. RESULTS: A total of 469 prisoners were diagnosed with TB over the 1.5-year period (incidence 955/100 000 person-years). Of 466 prisoners starting treatment, 48% completed treatment, 43% defaulted, 5% died and 4% were currently on treatment. During treatment, 12% of prisoners remaining in the same prison defaulted, 53% of transfers defaulted and 81% of those released were lost to follow-up. The odds of defaulting were 8.36 times greater among prisoners who were transferred during treatment. CONCLUSIONS:TB incidence and treatment default are high among Ugandan prisoners. Strategies to improve treatment completion and prevent multidrug resistance could include avoiding transfer of TBpatients, improving communications between prisons to ensure treatment follow-up after transfer and facilitating transfer to community clinics for released prisoners.
Authors: C Habeenzu; S Mitarai; D Lubasi; V Mudenda; T Kantenga; J Mwansa; J N Maslow Journal: Int J Tuberc Lung Dis Date: 2007-11 Impact factor: 2.373
Authors: Iacopo Baussano; Brian G Williams; Paul Nunn; Marta Beggiato; Ugo Fedeli; Fabio Scano Journal: PLoS Med Date: 2010-12-21 Impact factor: 11.069
Authors: Daniel E Winetsky; Diana M Negoescu; Emilia H DeMarchis; Olga Almukhamedova; Aizhan Dooronbekova; Dilshod Pulatov; Natalia Vezhnina; Douglas K Owens; Jeremy D Goldhaber-Fiebert Journal: PLoS Med Date: 2012-11-27 Impact factor: 11.069
Authors: Lilanganee Telisinghe; Salome Charalambous; Stephanie M Topp; Michael E Herce; Christopher J Hoffmann; Peter Barron; Erik J Schouten; Andreas Jahn; Rony Zachariah; Anthony D Harries; Chris Beyrer; Joseph J Amon Journal: Lancet Date: 2016-07-14 Impact factor: 79.321
Authors: K O Robsky; J Mukiibi; A Nalutaaya; P J Kitonsa; D Isooba; O Nakasolya; Y Baik; C E Kamoga; E A Kendall; A Katamba; D W Dowdy Journal: Int J Tuberc Lung Dis Date: 2021-06-01 Impact factor: 2.373
Authors: Stephanie M Topp; Clement N Moonga; Constance Mudenda; Nkandu Luo; Michael Kaingu; Chisela Chileshe; George Magwende; Jody S Heymann; German Henostroza Journal: Int J Equity Health Date: 2016-09-26
Authors: Stephanie M Topp; Clement N Moonga; Nkandu Luo; Michael Kaingu; Chisela Chileshe; George Magwende; S Jody Heymann; German Henostroza Journal: Health Policy Plan Date: 2016-05-24 Impact factor: 3.344